PCE

Making Sense of the Expanding Options in Metastatic Colorectal Cancer Care: Part 2

Episode Summary

In this podcast, two oncologists discuss subsequent therapy for metastatic colorectal cancer, and review cases to illustrate guideline-recommended management. Claim your credit at pce.is/GIGU.

Episode Notes

In this second of two podcasts, two oncologists discuss subsequent therapy for metastatic colorectal cancer, and review cases of patients with metastatic colorectal cancer to discuss testing for mutations and biomarkers, appropriate selection of treatment regimens, and management. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.

Contributors:

Joleen Hubbard MD

Cathy Eng, MD

Stephanie Andrews, MS, APRN-C

Ms Andrews: fees for non-CME/CE services: Genentech.

Dr Eng: consulting fees: Amgen, GlaxoSmithKline, Hoopika, Natera; contracted research (paid to institution): Merck, Pfizer.

Dr Hubbard: advisor: BeiGene; advisor/researcher: Bayer, Boston Biomedical, G1 Therapeutics, Hutchison MediPharma, Incyte, Merck, Pionyr Immunotherapeutics, Seagen, Senhwa Pharmaceuticals, Roche, Treos Bio, TriOncology, Trovogene.